N/A
N=50
Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum
Hyperemesis Gravidarum · Pregnancy Related
Bottom Line
View on ClinicalTrials.gov: NCT03950167 ↗Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Nov 2021
Primary outcome: Primary: Blood Cholecystokinin (CCK) Levels — 53.13; 54.55; 73.61; 81.24 picogram/mililiters (pg/ml) — p=0.05
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Müge Keskin
- Primary completion
- May 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Blood Cholecystokinin (CCK) Levels |
53.13; 54.55; 73.61; 81.24 | 0.05 |
| PRIMARY Gallbladder (GB) Wall Thickness |
2.10; 2.11; 2.51; 2.74 | 0.05 |
| PRIMARY Gallbladder (GB) Volume |
36.9; 33.69; 17.29; 18.33 | 0.05 |
| PRIMARY Gallbladder (GB) Ejection Fraction |
52.06; 45.46 | 0.05 |
Summary
This study evaluates the gallbladder functions and serum cholecystokinin levels in pregnant women diagnosed with hyperemesis gravidarum. Half of the participants are healthy pregnant women and half of the participants are pregnant women diagnosed with hyperemesis gravidarum. Two groups will be compared by means of gallbladder functions and serum cholecystokinin levels.
Eligibility Criteria
Inclusion Criteria
- gestation week between 6 and 14 weeks,
- singleton pregnancy with a live embryo,
- healthy women without any medical disorders,
Exclusion Criteria
- any systemic disease,
- gallbladder disease
- any psychological disorder that can cause vomiting,
- multiple gestation
Data sourced from ClinicalTrials.gov (NCT03950167). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.